Acute toxicity evolution during ozonation of mono-chlorophenols and initial identification of highly toxic intermediates

2019 ◽  
Vol 21 (9) ◽  
pp. 1509-1518 ◽  
Author(s):  
Dehua Ma ◽  
Jianjian Wei ◽  
Hongbo Zhang ◽  
Yukun Zhou ◽  
Jinyou Shen ◽  
...  

Acute toxicity changes during ozonation of 2-chlorophenol (2-CP), 3-chlorophenol (3-CP) and 4-chlorophenol (4-CP) under various conditions were studied using the luminescence inhibition test.




RSC Advances ◽  
2017 ◽  
Vol 7 (60) ◽  
pp. 37636-37642 ◽  
Author(s):  
Qiao-Feng Zheng ◽  
Mo Yu ◽  
Shu-Shen Liu ◽  
Fu Chen

Hormesis is a biphasic concentration–response relationship. During the luminescence inhibition test ofVibrio qinghaiensissp.-Q67 (Q67), some organic solvents display the hormesis phenomenon.



2007 ◽  
Vol 55 (10) ◽  
pp. 217-225 ◽  
Author(s):  
G. Iskender ◽  
A. Sezer ◽  
I. Arslan-Alaton ◽  
F. Germirli Babuna ◽  
O.S. Okay

The effect of applying ozonation and perozonation to antibiotic cefazolin-Na formulation effluents were investigated in this study. Twenty minutes of ozonation at a rate of 1,500 mg/L-h was observed to remove COD by 38%, whereas a COD removal efficiency of 40% was achieved via H2O2 enhanced ozonation (same conditions + 31.25 mM H2O2). Both of the pretreatment alternatives were monitored to elevate the BOD5/COD ratio from 0.01 to 0.08. The initially inert COD was reduced by 38% using ozonation and by 60% employing H2O2 enhanced ozonation. In terms of the lowest achievable effluent COD levels after bio-treatment, ozonation was observed to yield a residual COD of 205 mg L−1, while a residual COD of 135 mg L−1 was involved for perozonation. According to the results of acute toxicity on Phaedactylum tricornutum, ozonated and perozonated samples exhibited more toxicity than the untreated effluent after 4 days. The activated sludge inhibition test demonstrated that both of the pretreatment alternatives efficiently eliminated the inhibition of investigated formulation effluent.



2001 ◽  
Vol 88 (2) ◽  
pp. 59-66 ◽  
Author(s):  
Pauline M. Ryan ◽  
John P. Kelly1Note ◽  
Philip L. Chambers ◽  
Brian E. Leonard


2012 ◽  
Author(s):  
Michael R. Capawana ◽  
Mary E. Walsh ◽  
Evan B. Michel ◽  
Sarah Backe ◽  
Amy C. Orecchia


Planta Medica ◽  
2016 ◽  
Vol 81 (S 01) ◽  
pp. S1-S381
Author(s):  
GM Avila-Villarreal ◽  
DE Giles-Rivas ◽  
B Aguilar-Guadarrama ◽  
P Castillo-España ◽  
S Estrada-Soto


1968 ◽  
Vol 20 (03/04) ◽  
pp. 588-595 ◽  
Author(s):  
E. B Goodsell ◽  
R. A Krause ◽  
E. T Kimura

SummaryUbiquin (oligo-3-(N-methylmorpholinium)-l,2-propylene oxide chloride) is a stable, water soluble, active heparin antagonist producing prompt neutralization when administered in a 1:1 ratio to rats and dogs. Initial studies indicate that it is devoid of any effect on coagulation per se; nor are there any obvious side effects manifested during the process of neutralization. The acute toxicity is less than that of other compounds in use: toluidine blue, protamine and hexadimethrine.



1964 ◽  
Vol 11 (02) ◽  
pp. 485-496 ◽  
Author(s):  
B. J Koszewski ◽  
H Vahabzadeh

SummaryA case of hypercoagulability syndrome in a 35 years old male is reported. An abnormal heparin resistance was found which could be defined by means of a heparin clot-inhibition test as a deficiency in heparin co-factor. The required anticoagulant doses of heparin were forty times as high as in cases with intact heparin co-factor. The factor seemed to be used up in the process of coagulation, as plasma, but not serum, was able to correct the deficiency in vitro. Plasma infusions were helpful for four days, but a complete recovery was achieved only after an intensive course of fever therapy.The phenomenon of blood clotting should be regarded as a dynamic process which is facilitated by an array of clot promoting factors and opposed by a system of natural anticoagulants.



1981 ◽  
Vol 46 (04) ◽  
pp. 734-739 ◽  
Author(s):  
M C Coots ◽  
M A Miller ◽  
H I Glueck

SummaryThe plasmas of six patients with prolonged activated partial thromboplastin times were studied in detail. In five of the six, the Russell’s viper venom and prothrombin times were likewise prolonged. Five of the patients had documented systemic lupus erythematosus; one lacked the necessary criteria for this diagnosis. On quantitation, factor XI was decreased in all six; factors X and XII were diminished in five of the six. When tested for inhibitory activity, plasma from each of the patients prolonged the celite eluate inhibition test for factor XII and/or XI inhibition. In the formation of the Xa-V-phospholipid-Ca2+ complex (prothrombinase), factors X and Xa were inhibited to a greater degree than factor V or the phospholipid. Finally, each plasma was isofocused, the inhibitory fractions were identified and the clotting factor specificity of each inhibitory peak was determined.Fractions inhibitory against factors XI and XII isofocused with the IgG in each patient’s plasma. Based on the data presented from these six patients, the “lupus inhibitor” is in fact a heterogeneous collection of inhibitors directed against factors XII, XI and X rather than a homogeneous entity.



Sign in / Sign up

Export Citation Format

Share Document